Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Leerink Partners analyst Mani Foroohar has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Invest with ...

Since the market is focusing on the COVID vaccine performance and overlooking the revenue opportunity that Moderna's product candidates have, I believe long-term investors are likely to get rewarded.

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...

Companies that bring products to market quickly and efficiently are better positioned to succeed and improve patient outcomes. Or so the industry wisdom goes. The go-to-market feat of Moderna ...

Rather than spending to explore new products ... that key risks specific to Moderna include the "potential for greater-than-anticipated drop-off in the COVID market, possible failure to show ...

Moderna also implemented a portfolio prioritization and cost efficiency program to reduce annual R&D expenses and focus on products that are either nearing approval or already in the market.

The mRNA pioneer sees considerable uncertainty in the vaccine market. However, Moderna still expects 10 product approvals over the next three years that could fuel growth. The conventional ...